While soy typically takes up cholesterol research in the legume family, researchers at Tulane University and Arizona State University devised a meta-analysis evaluating non-soy legume consumption and any effect those foods may have had blood lipids.
A meta-analysis in the February 2011 issue of Nutrition, Metabolism, and Cardiovascular Diseases reinforces the potential for non-soy legumes and cholesterol management.
While soy typically takes up cholesterol research in the legume family, researchers at Tulane University (New Orleans) and Arizona State University devised a meta-analysis of randomized controlled trials evaluating non-soy legume consumption and any effect those foods may have had blood lipids.
Using MEDLINE and the Cochrane Collaboration’s Central Register of Controlled Clinical Trials, the researchers gathered 10 randomized clinical trials evaluating non-soy legume diet versus control for a minimum three week’s duration with reported blood lipid changes.
With data from a combined 268 participants in the trials, the research team determined that, compared to placebo, legume diets provided significant reductions of total and low-density lipoprotein (LDL) cholesterol. Total cholesterol was reduced by an average 11.6 mg/dL and LDL cholesterol (commonly known as “bad” cholesterol) was reduced by an average 8 mg/dL.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.